Mariana Floria
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mariana Floria has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Anca Ouatu
Department of Internal Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iaşi, Romania
1 shared publication - Ciprian Rezus
Department of Internal Medicine, Grigore T. Popa University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania
1 shared publication - Daniela Maria Tanase
Department of Internal Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iaşi, Romania
1 shared publication - Diana Popescu
Faculty of General Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania
1 shared publication - Minerva Codruta Badescu
“Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, Romania
1 shared publication - Nicoleta Dima
Department of Internal Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iaşi, Romania
1 shared publication
Latest Publications
- Open Access
- 20 September 2024
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (9) , 1002
Optimizing Anticoagulation in Valvular Heart Disease: Navigating NOACs and VKAs
Background/Objectives: Non-vitamin K antagonist oral anticoagulants (NOACs) have demonstrated similar effectiveness and safety profiles to vitamin K antagonists (VKAs) in treating nonvalvular atrial fibrillation (AF). Given their favorable pharmacological profile, including the rapid onset and offset of action, fixed dosing, and predictable pharmacokinetics with a consistent dose-response relationship, reducing the need for frequent blood tests, researchers have investigated the potential of NOACs in patients with AF and valvular heart disease (VHD). Methods: Clinical trials, excluding patients with mechanical prosthetic valves or moderate/severe mitral stenosis, have shown the benefits of NOACs over VKAs in this population. However, there is a need for further research to determine if these findings apply to mechanical valve prostheses and NOACs. Results: Several ongoing randomized controlled trials are underway to provide more definitive evidence regarding NOAC treatment in moderate to severe rheumatic mitral stenosis. Importantly, recent trials that included patients with atrial fibrillation and bioprosthetic valves (also transcatheter heart valves) have provided evidence supporting the safety of NOACs in this specific patient population. Ongoing research aims to clearly define the specific scenarios where NOACs can be safely and effectively prescribed for various types of VHD, including moderate/severe mitral stenosis and mechanical valves. Conclusions: The aim of this review is to accurately identify the specific situations in which NOACs can be prescribed in patients with VHD, with a focus centered on each type of valvulopathy.
- 20 September 2024
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (9) , 1002
Open AccessOptimizing Anticoagulation in Valvular Heart Disease: Navigating NOACs and VKAs
Background/Objectives: Non-vitamin K antagonist oral anticoagulants (NOACs) have demonstrated similar effectiveness and safety profiles to vitamin K antagonists (VKAs) in treating nonvalvular atrial fibrillation (AF). Given their favorable pharmacological profile, including the rapid onset and offset of action, fixed dosing, and predictable pharmacokinetics with a consistent dose-response relationship, reducing the need for frequent blood tests, researchers have investigated the potential of NOACs in patients with AF and valvular heart disease (VHD). Methods: Clinical trials, excluding patients with mechanical prosthetic valves or moderate/severe mitral stenosis, have shown the benefits of NOACs over VKAs in this population. However, there is a need for further research to determine if these findings apply to mechanical valve prostheses and NOACs. Results: Several ongoing randomized controlled trials are underway to provide more definitive evidence regarding NOAC treatment in moderate to severe rheumatic mitral stenosis. Importantly, recent trials that included patients with atrial fibrillation and bioprosthetic valves (also transcatheter heart valves) have provided evidence supporting the safety of NOACs in this specific patient population. Ongoing research aims to clearly define the specific scenarios where NOACs can be safely and effectively prescribed for various types of VHD, including moderate/severe mitral stenosis and mechanical valves. Conclusions: The aim of this review is to accurately identify the specific situations in which NOACs can be prescribed in patients with VHD, with a focus centered on each type of valvulopathy.